A Phase 2A Single Dose, Open Label Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Subjects With Chronic Kidney Disease (CKD), Stages 3 and 4
Latest Information Update: 30 Jun 2022
At a glance
- Drugs Vadadustat (Primary)
- Indications Renal failure
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Akebia Therapeutics
- 14 Jan 2021 New trial record